RedHill Biopharma (RDHL) Change in Receivables (2017 - 2023)

RedHill Biopharma (RDHL) has reported Change in Receivables for 7 consecutive years, with $4.0 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Change in Receivables rose 150.52% year-over-year to $4.0 million in Q2 2023; TTM through Jun 2023 was $30.9 million, a 943.85% increase from a year earlier, with the FY2025 full-year figure at $2.3 million, up 4244.23% from the prior year.
• Change in Receivables was $4.0 million for Q2 2023 at RedHill Biopharma, down from $27.7 million in the prior quarter.
• Over five years, Change in Receivables peaked at $27.7 million in Q1 2023 and troughed at -$16.9 million in Q2 2020.
• A 5-year average of -$108000.0 and a median of -$150500.0 in 2019 frame the typical range for Change in Receivables.
• The widest YoY moves for Change in Receivables: up 5487.27% in 2020, down 4371.35% in 2020.
• Over 5 years, Change in Receivables stood at -$363000.0 in 2019, then slumped by 4371.35% to -$16.2 million in 2020, then soared by 89.9% to -$1.6 million in 2021, then soared by 190.55% to $1.5 million in 2022, then soared by 166.06% to $4.0 million in 2023.
• The last three Change in Receivables figures came in at $4.0 million (Q2 2023), $27.7 million (Q1 2023), and $1.5 million (Q4 2022), per Business Quant data.